Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E; GETAID and the SPARE-Biocycle research group. Louis E, et al. Among authors: picon l. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):215-227. doi: 10.1016/S2468-1253(22)00385-5. Epub 2023 Jan 11. Lancet Gastroenterol Hepatol. 2023. PMID: 36640794 Free PMC article. Clinical Trial.
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
Uzzan M, Bresteau C, Laharie D, Stefanescu C, Bellanger C, Carbonnel F, Serrero M, Viennot S, Nachury M, Amiot A, Altwegg R, Picon L, Nahon S, Vuitton L, Ah Soune P, Kirchgesner J, Peyrin-Biroulet L, Bouhnik Y; GETAID-TALC Study Group. Uzzan M, et al. Among authors: picon l. Aliment Pharmacol Ther. 2021 Aug;54(3):312-319. doi: 10.1111/apt.16463. Epub 2021 Jun 20. Aliment Pharmacol Ther. 2021. PMID: 34151448
Development of a New Index to Assess Small Bowel Inflammation Severity in Crohn's Disease Using Magnetic Resonance Enterography.
Bouhnik Y, Le Berre C, Zappa M, Lewin M, Boudiaf M, Zagdanski AM, Frampas E, Oudjit A, Scotto B, Tissier M, Annet L, Aufort S, Yzet T, Cuilleron M, Baudin G, Abitbol V, Cosnes J, Bourreille A, Mary JY; GETAID CDMRIS Study Group. Bouhnik Y, et al. Crohns Colitis 360. 2022 Feb 5;4(1):otac004. doi: 10.1093/crocol/otac004. eCollection 2022 Jan. Crohns Colitis 360. 2022. PMID: 36777552 Free PMC article.
Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID.
Bacha RA, Bouhnik Y, Serrero M, Filippi J, Roblin X, Bourrier A, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Mathieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Berre CL, Laharie D, Nachury M, Amiot A; GETAID-patient experience study group. Bacha RA, et al. Dig Liver Dis. 2023 Dec;55(12):1632-1639. doi: 10.1016/j.dld.2023.05.008. Epub 2023 May 26. Dig Liver Dis. 2023. PMID: 37246095 Free article.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif.
Guillo L, Savoye G, Amiot A, Gilletta C, Nachury M, Dib N, Bourreille A, Roblin X, Caillo L, Allez M, Picon L, Hébuterne X, Seksik P, Chupin A, Buisson A, Brixi H, Altwegg R, Simon M, Amil M, Laharie D, Bouguen G, Serrero M, Elgharabawy Y, Peyrin-Biroulet L; EXTRA Study Group. Guillo L, et al. Among authors: picon l. Clin Transl Gastroenterol. 2023 Dec 1;14(12):e00607. doi: 10.14309/ctg.0000000000000607. Clin Transl Gastroenterol. 2023. PMID: 37523417 Free PMC article.
American Speech-Language-Hearing Association Clinical Practice Guideline: Cognitive Rehabilitation for the Management of Cognitive Dysfunction Associated With Acquired Brain Injury.
Guideline Development Panel, Brown J, Kaelin D, Mattingly E, Mello C, Miller ES, Mitchell G, Picon LM, Waldron-Perine B, Wolf TJ, Frymark T, Bowen R. Guideline Development Panel, et al. Among authors: picon lm. Am J Speech Lang Pathol. 2022 Nov 16;31(6):2455-2526. doi: 10.1044/2022_AJSLP-21-00361. Epub 2022 Nov 14. Am J Speech Lang Pathol. 2022. PMID: 36373898
How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients.
Brunet-Houdard S, Monmousseau F, Berthon G, Des Garets V, Laharie D, Picon L, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-Poisson C, Dib N, Rusch E, Aubourg A; COQC-PIT Study Group. Brunet-Houdard S, et al. Among authors: picon l. Scand J Gastroenterol. 2022 Nov;57(11):1312-1320. doi: 10.1080/00365521.2022.2085057. Epub 2022 Jun 18. Scand J Gastroenterol. 2022. PMID: 35722732
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study.
Poullenot F, Amiot A, Nachury M, Viennot S, Altwegg R, Bouhnik Y, Abitbol V, Nancey S, Vuitton L, Peyrin-Biroulet L, Biron A, Fumery M, Picon L, Vidon M, Reenaers C, Serrero M, Savoye G, Beaugerie L, Rivière P, Laharie D. Poullenot F, et al. Among authors: picon l. J Crohns Colitis. 2022 Nov 1;16(10):1523-1530. doi: 10.1093/ecco-jcc/jjac061. J Crohns Colitis. 2022. PMID: 35512337
162 results